Please login to the form below

Not currently logged in
Email:
Password:

Ronald Berenson to lead Aequus BioPharma

Joins the Cell Therapeutics subsidiary as president and CEO

Cell Therapeutics' US subsidiary Aequus BioPharma has appointed Ronald Berenson as president and CEO.

In his new role he will be tasked with expanding Washington State-based Aequus' GlycoPolymer technology, which aims to create novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current treatments.

Berenson said: "There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and compliance continue to be issues with therapeutic proteins due to the need for frequent injections.

"I believe that Aequus's novel approach could address these challenges with the potential to be applied to a wide spectrum of therapeutics."

Berenson, who was most recently an Entrepreneur in Residence at the University of Washington, has spent more than 20 years in senior biotech management roles.

During this time he co-founded HemaQuest Pharmaceuticals, serving as president and CEO for its first three years, and founded the oncology-focused biotech companies Xcyte Therapies and CellPro.

11th December 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics